Skip to main content

Swiss biotechnology company

Serono

(SRA)

said it has hired Goldman Sachs as an adviser to help it consider strategic alternatives.

TheStreet Recommends

The company's statement came after a published report said Serono was looking into the possibility of merging with another firm.

Serono said there was no assurance a transaction will be completed. In 2004, worldwide revenue was $2.46 billion and net income was $494.2 million. The company's products are sold in more than 90 countries.

Shares of Serono were gaining $1.28, or 7.8%, to $17.72 in premarket trading Tuesday.